Skip to content

Microdosing: all studies

Page 6 of 56: studies 51 to 60 of 555, newest first. Back to the microdosing overview

Research

Phase 0 Experimental Medicine Study of Direct Intratarget Pulmonary Microdosing of nlrp3/1 Inflammasome Inhibitor ads032: the Micro Study. A Protocol Paper

Clinical Research and Clinical Trials November 18, 2025 Tom M. Quinn, A Bruce, S Dickson et al.

Introduction High attrition in drug development remains a significant challenge for research and development organisations worldwide. Most novel drug compounds fail at an early stage, often without knowledge of target engagement or molecular efficacy at diseased tissue level. Phase 0 trials provide an opportunity to provide mechanistic data in a small number of patients at the earliest stage of...

Enhancing fertilizer-use-efficiency through fertilizer microdosing as climate-smart practices among crop farmers in North Central, Nigeria

Frontiers in Sustainable Food Systems November 18, 2025 Adetomiwa Kolapo, Isaac Busayo Oluwatayo, Wale Ayojimi et al.

The impact of climate change, soil fertility depletion, and land degradation has necessitated the continuous use of fertilizer to enhance crop productivity. However, the high cost of fertilizer, coupled with improper use of fertilizer leading to environmental issues, has encouraged efficient use of fertilizer. This study draws on farm-level data to assess the link between the implementation of...

DOI: 10.3389/fsufs.2025.1497716 (opens in new tab) Full text (opens in new tab) Fertilizer microdosing Fertilizer use efficiency Climate change 2sls +1

Statistical Analysis Plan (SAP): A randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorder (LSDDEP2)

Open Mind November 17, 2025 Dimitri Daldegan-Bueno, Suresh Muthukumaraswamy, Alana Cavadino preprint

The analyses described in this SAP will assess the efficacy and safety of LSD (MB-22001) in comparison with active placebo (caffeine). The analysis described cover those for the primary, secondary and safety endpoints described in the Protocol.

Microdosing Psilocybin for Major Depressive Disorder: Study Protocol for a Phase II Double-Blind Placebo-Controlled Randomized Partial Crossover Trial

November 16, 2025 Zeina Beidas, Anya Ragnhildstveit, Adam Blackman et al. preprint

Background: Major depressive disorder (MDD) is the leading cause of disability worldwide, affecting roughly 322 million people. Recently, doses of psilocybin have shown promise in treating mood disorders, sparking interest in other dosing practices. According to anecdotal reports and observational studies, microdosing psilocybin yields benefits to mental health; however, rigorously controlled...

LSD microdosing in major depressive disorder: results from an open-label trial

Neuropharmacology November 5, 2025 Dimitri Daldegan-Bueno, C Donegan, Rachael Sumner et al. 4 citations

Major depressive disorder (MDD) affects approximately 5 % of the global population. Classic psychedelics have shown promise in treating various mental health disorders. This study evaluated the feasibility and tolerability of an 8-week regimen of microdosed lysergic acid diethylamide (LSD) as a treatment for major depressive disorder in an open-label phase 2A trial (LSDDEP1). Nineteen...

Microdosing psilocybin and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials

Neuropharmacology November 2, 2025 Luisa Prochazkova, Josephine Marschall, Michiel van Elk et al. 2 citations

BackgroundTaking very small doses of psychedelics (LSD, truffles) over an extended period became prevalent in Western societies for its alleged cognitive benefit, including enhanced creativity. However, in the absence of robust, double-blind-controlled quantitative studies, such claims remain anecdotal.MethodsHere we present results from 3 double-blind placebo-controlled longitudinal trials...

Modeling Whole-Body Dynamic PET Microdosing Data to Predict the Whole-Body Pharmacokinetics of Glyburide in Humans.

Clinical Pharmacokinetics November 1, 2025 Léa Comin, Solène Marie, Moreno Ursino et al.

Whole-body dynamic (WB4D) positron emission tomography (PET) imaging data using radiolabeled analogs of drugs are mostly analyzed using descriptive approaches, with no relationship to traditional pharmacokinetic studies based on blood sampling. Here, we build a pharmacokinetic (PK) model from WB4D PET data obtained using a microdose of radiolabeled glyburide ([11C]glyburide) in humans, aiming...

“It Fueled the Fire to Who I Am Now”: Exploring Motivations for Microdosing Psychedelics

Journal of Drug Issues October 31, 2025 Blake Beaton

The emergence of microdosing introduced a novel approach to consuming classic psychedelic substances, such as LSD (lysergic acid diethylamide) and psilocybin mushrooms, in ways previously unconventional. Whereas traditional illicit substance use often seeks euphoric experiences, microdosing deliberately avoids such effects in favor of perceived self-enhancing benefits. Increasingly common in...

Cognitive and subjective effects of psilocybin microdosing: Results from two double-blind placebo-controlled longitudinal trials

Neuropharmacology October 17, 2025 Luisa Prochazkova, Josephine Marschall, Dominique P. Lippelt et al. 3 citations

ObjectiveMicrodosing psychedelics has been widely reported to enhance focus and problem-solving, sparking interest in its potential to treat attentional disorders such as ADHD. However, existing studies largely rely on anecdotal evidence and lack adequate placebo control.MethodsThis study contributes to the literature by examining the longitudinal effects of microdosing psilocybin truffles in...

DOI: 10.1016/j.neuropharm.2025.110722 (opens in new tab) Psilocybin Cognition Hallucinogen Cognitive assessment system +3

Analysis of Serotonin in Caenorhabditis Elegans Subjected to Micro-Dosing with Psilocybin| Iris Publishers

Insights in Chemistry and Biochemistry October 15, 2025 Douglas B. Craig

method was developed for the analysis of serotonin in Caenorhabditis elegans. Samples were subjected to solvent-solvent extraction from basic conditions into n-heptanol. The serotonin was then back-extracted into acetic acid, the solution diluted into basic buffer, and labelled with 3-(2-furoyl) quinoline-2-carboxaldehyde in the presence of cyanide. The sample was analyzed by capillary...

DOI: 10.33552/icbc.2025.03.000562 (opens in new tab) Caenorhabditis elegans Iris biosensor Capillary electrophoresis Fluorescence +4